Cargando…

Immune checkpoint inhibitors induced colitis, stay vigilant: A case report

BACKGROUND: Colitis is one of the immune-related side effects of immunotherapy. Usually, such type of side effect was reported to develop within a few weeks of treatment initiation, our case started within a few days. CASE SUMMARY: We present a case of a 37-year-old gentleman with bright red loose s...

Descripción completa

Detalles Bibliográficos
Autores principales: Abu Khalaf, Suha, Albarrak, Abdulmajeed, Yousef, Mohamad, Tahan, Veysel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340999/
https://www.ncbi.nlm.nih.gov/pubmed/32699584
http://dx.doi.org/10.4251/wjgo.v12.i6.699
_version_ 1783555142013943808
author Abu Khalaf, Suha
Albarrak, Abdulmajeed
Yousef, Mohamad
Tahan, Veysel
author_facet Abu Khalaf, Suha
Albarrak, Abdulmajeed
Yousef, Mohamad
Tahan, Veysel
author_sort Abu Khalaf, Suha
collection PubMed
description BACKGROUND: Colitis is one of the immune-related side effects of immunotherapy. Usually, such type of side effect was reported to develop within a few weeks of treatment initiation, our case started within a few days. CASE SUMMARY: We present a case of a 37-year-old gentleman with bright red loose stools, abdominal pain, and tenesmus. A diagnosis of colitis was made based on endoscopic and histologic findings. Treatment was thereafter continued with oral steroids and discontinuation of the immunotherapy medications. Symptoms resolved after starting the treatment and the patient continued to be symptom-free on subsequent follow-up. The unique about this case report is that the patient developed bloody diarrhea within five days of the 1(st) immunotherapy cycle, and the patient was on combined ipilimumab and nivolumab. CONCLUSION: Immunotherapy related complications might occur within days from being on immunotherapy; we need more research to open the way for future pathological and clinical research to further understand the pathophysiology behind it.
format Online
Article
Text
id pubmed-7340999
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-73409992020-07-21 Immune checkpoint inhibitors induced colitis, stay vigilant: A case report Abu Khalaf, Suha Albarrak, Abdulmajeed Yousef, Mohamad Tahan, Veysel World J Gastrointest Oncol Case Report BACKGROUND: Colitis is one of the immune-related side effects of immunotherapy. Usually, such type of side effect was reported to develop within a few weeks of treatment initiation, our case started within a few days. CASE SUMMARY: We present a case of a 37-year-old gentleman with bright red loose stools, abdominal pain, and tenesmus. A diagnosis of colitis was made based on endoscopic and histologic findings. Treatment was thereafter continued with oral steroids and discontinuation of the immunotherapy medications. Symptoms resolved after starting the treatment and the patient continued to be symptom-free on subsequent follow-up. The unique about this case report is that the patient developed bloody diarrhea within five days of the 1(st) immunotherapy cycle, and the patient was on combined ipilimumab and nivolumab. CONCLUSION: Immunotherapy related complications might occur within days from being on immunotherapy; we need more research to open the way for future pathological and clinical research to further understand the pathophysiology behind it. Baishideng Publishing Group Inc 2020-06-15 2020-06-15 /pmc/articles/PMC7340999/ /pubmed/32699584 http://dx.doi.org/10.4251/wjgo.v12.i6.699 Text en ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Case Report
Abu Khalaf, Suha
Albarrak, Abdulmajeed
Yousef, Mohamad
Tahan, Veysel
Immune checkpoint inhibitors induced colitis, stay vigilant: A case report
title Immune checkpoint inhibitors induced colitis, stay vigilant: A case report
title_full Immune checkpoint inhibitors induced colitis, stay vigilant: A case report
title_fullStr Immune checkpoint inhibitors induced colitis, stay vigilant: A case report
title_full_unstemmed Immune checkpoint inhibitors induced colitis, stay vigilant: A case report
title_short Immune checkpoint inhibitors induced colitis, stay vigilant: A case report
title_sort immune checkpoint inhibitors induced colitis, stay vigilant: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340999/
https://www.ncbi.nlm.nih.gov/pubmed/32699584
http://dx.doi.org/10.4251/wjgo.v12.i6.699
work_keys_str_mv AT abukhalafsuha immunecheckpointinhibitorsinducedcolitisstayvigilantacasereport
AT albarrakabdulmajeed immunecheckpointinhibitorsinducedcolitisstayvigilantacasereport
AT yousefmohamad immunecheckpointinhibitorsinducedcolitisstayvigilantacasereport
AT tahanveysel immunecheckpointinhibitorsinducedcolitisstayvigilantacasereport